908 Devices shares surge 14.81% premarket after strong preliminary results show 17% revenue growth and positive EBITDA.

908 Devices Inc. (NASDAQ: MASS) surged 14.81% in premarket trading following the release of strong preliminary financial results for Q4 2025 and the full year. The company reported $17.2 million in Q4 revenue, a 20% year-over-year increase, driven by robust performance in U.S. state/local markets, international adoption of its VipIR product, and federal/defense sales. Full-year revenue reached $56 million, reflecting 17% growth, with positive Adjusted EBITDA in Q4. CEO Kevin Knopp highlighted the company’s strategic shift to a "stronger, simpler, and more profitable" model focused on frontline chemical detection, citing favorable macro trends such as increased funding for opioid crisis solutions and defense budgets. The preliminary results, though unaudited, align with the high end of revenue guidance and underscore the company’s positioning for future growth, directly supporting the sharp premarket price increase.